License agreement on NK cell therapy technology

This agreement will bring significant benefit to the targeted treatment of patients suffering from cancer.  The agreement not only opens up new opportunities for the development of NK-antibody combination therapies but also has a significant positive impact on the production time of Glycostem’s lead product oNKord® and its second (CAR-NK) and third (TCR-NK) generation therapies – viveNK™. Read the whole press release here.

 

 

 

 

 

 

 

 

Back

Related news

Glycostem appoints new Chief Medical Officer

Dr. Kai Pinkernell, M.D. joins Glycostem’s leadership team as Chief Medical Officer

View article

Glycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem’s oNKord® and CAR-NK treatments

Under the terms of the agreement, Pieris will provide Glycostem with Anticalin constructs against immune targets to be combined with Glycostem’s oNKord® technology to study the combined potential of the technologies in the treatment of solid tumors.

View article

2020 highlights Pivot Park Community

Read here a short summary of the 2020 highlights of our Community members

View article